– USA, MA – VBI Vaccines Inc. (NASDAQ:VBIV), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced the appointment of Joanne Cordeiro to its Board of Directors. Ms. Cordeiro most recently served as Chief Human Resources Officer and Executive Vice President of Human Resources at Shire PLC, after joining the company in 2011.
“Joanne is a fantastic addition to our Board, bringing with her the experience of strategic partnership with the Executive Team and the Board of Shire to execute the company’s corporate strategy,” said Jeff Baxter, President and CEO of VBI. “Her unique expertise in organizational vision, human capital strategies, ethics, and cultural topics with a focus on shareholder value will be of tremendous benefit to VBI as we progress through the potentially transformative clinical, regulatory, and commercial milestones over the next few years.”
Prior to joining Shire in 2011, Ms. Cordeiro served in various human resources management and executive recruitment roles at Teradyne Inc., Covansys Corporation, Avid Technology, Inc., and Sybase Inc.
“Having spent much of my career focusing on organizational transformation within global teams, I am extremely pleased to join VBI’s Board of Directors at such a pivotal time for the company,” said Ms. Cordeiro. “I look forward to working with the team to capitalize on the potential of the pipeline programs and the company as a whole.”
About VBI Vaccines Inc.
VBI Vaccines Inc. (Nasdaq:VBIV) is a commercial-stage biopharmaceutical company developing a next generation of vaccines to address unmet needs in infectious disease and immuno-oncology. VBI is advancing the prevention and treatment of hepatitis B, with the only commercially-approved trivalent hepatitis B vaccine, Sci-B-Vac, which is approved for use in Israel and 10 other countries and is currently in a Phase 3 study in the U.S., Europe, and Canada, and with an immuno-therapeutic in development for a functional cure for chronic hepatitis B. VBI’s eVLP Platform technology allows for the development of enveloped virus-like particle vaccines that closely mimic the target virus to elicit a potent immune response. Integrating its cytomegalovirus expertise with the eVLP platform technology, VBI’s lead eVLP vaccine candidates include a prophylactic CMV vaccine candidate and a therapeutic glioblastoma vaccine candidate. VBI is headquartered in Cambridge, MA with research operations in Ottawa, Canada and research and manufacturing facilities in Rehovot, Israel.
For more information : https://www.vbivaccines.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.